RecruitingPhase 4NCT06763172

Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI

Measure Striatal Adenosine-dopamine Receptors Interactions: from Molecule to Behaviors


Sponsor

Hsiao-Ying Wey

Enrollment

12 participants

Start Date

May 17, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This research study aims to determine whether and how caffeine intake affects learning process through reward feedback compared to placebo. The data acquired from this study would improve our understanding on the consequence and mechanism of caffeine intake in the aspect of learning process. Participants will perform a reinforcement learning task (i.e. Probabilistic Selection Task) and a motor inhibition task (i.e. Go/NoGo task) in a brain scan. The scan will be done with the Siemens Biograph mMR positron emission tomography (PET)/ magnetic resonance imaging (MRI) 3 Tesla scanner. The PET allows us to see the changes in the "reward signals" - dopamine - in the brain using a radioactive dye called \[11C\]Raclopride. The MRI, on the other hand, enables us to take detailed pictures of the brain activities during cognitive tasks using a high-powered magnet. Reviewing these pictures will help us understand the influence of caffeine on reward signals and brain activities during the learning process.


Eligibility

Min Age: 18 YearsMax Age: 45 Years

Inclusion Criteria5

  • Age ≥ 18 and ≤ 45.
  • Habitual caffeine intake ≥ 100 mg and ≤ 450 mg daily.
  • Non-smokers.
  • Clinically healthy.
  • Have normal vision or corrected to normal vision.

Exclusion Criteria17

  • Pregnant or lactating women.
  • Women using hormonal contraceptives.
  • BMI \< 18.5 or \> 29.9
  • Sleep disturbance or extreme chronotype.
  • Urine test positive on one of the following substances: benzoylecgonine, morphine, d-Methamphetamine, d-Amphetamine, Benzodiazepines, Secobarbital, Methadone, Buprenorphine Glucuronide, Nortriptyline, MDMA, Oxycodone, PCP, Propoxyphene, and Cannabis/THC
  • Diagnosis of depression, anxiety, psychosis, or neurologic disorders in the last 5 years.
  • Heart or cardiovascular diseases.
  • Diabetes or other metabolic diseases.
  • Under chronic medications, for instance, painkiller and steroid.
  • Allergy to lactose (main ingredient of blank control dose)
  • Incapable to operate the tasks or comprehend the study information in English.
  • Metallic foreign bodies such as cardiac pacemakers, perfusion pumps, aneurysm clips, metallic tattoos anywhere on the body, tattoos near the eye.
  • Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions
  • Inability to lie flat on scanner bed for about 90 min as assessed by physical examination and medical history (e.g. arthritis)
  • Recent exposure to radiation (i.e., PET from other research studies) that, when combined with this study, would be above the allowable limits
  • Pregnancy or breastfeeding: A negative serum or urine pregnancy test is required on the day of the PET procedure
  • Body weight of \> 300 lbs (weight limit of the MRI scanner table)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCaffeine (200 mg)

Caffeine (200mg) will be administered per os 20 minutes prior to the PET/fMRI data acquisition.

DRUGPlacebo

Lactose tablet will be administered per os 20 minutes prior to the PET/fMRI data acquisition.


Locations(1)

Athinoula A. Martinos Center for Biomedical Imaging

Charlestown, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06763172


Related Trials